{"nctId":"NCT01822548","briefTitle":"Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes","startDateStruct":{"date":"2010-10"},"conditions":["Type 2 Diabetes"],"count":64,"armGroups":[{"label":"Vildagliptin & metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Vildagliptin","Drug: Metformin"]},{"label":"Glibenclamide & metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glibenclamide","Drug: Metformin"]}],"interventions":[{"name":"Vildagliptin","otherNames":["LAF237A"]},{"name":"Glibenclamide","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age equal or above 35 years;\n* Diagnosis of type 2 diabetes mellitus as defined by the American Diabetes Association , with at least one year of disease duration at the time of the screening visit;\n* Blood glucose lowering treatment with Metformin alone (monotherapy) at a stable dose of at least 1.5 g/day (or maximum tolerated dose) in the 3 months prior to the screening visit;\n* Insufficient metabolic control as defined by recent (last six months) HbA1c ≥ 7% in any peripheral laboratory and confirmed at the time of the screening;\n* Absence of a recent clinically-relevant progression of micro- and macro-vascular complications (see exclusion criteria);\n* Written informed consent to participate to the study.\n\nExclusion criteria:\n\n* Age below 35 years\n* Type 1 diabetes or other causes of diabetes (pancreatectomy, gestational diabetes, etc.)\n* HbA1c \\< 7% or ≥ 9% at the screening visit\n* Treatment with any blood glucose lowering treatment other than Metformin in the six months before screening visit\n* BMI \\< 20 or ≥ 40 kg/m2, or current/ past history of clinically-relevant eating disorders (including -but no limited to- nervous anorexia, bulimia, binge-eating disorders, etc.)\n* Significant progression of diabetic macro-angiopathy or cardiovascular disease in the six months prior to study visit\n* Significant progression of diabetic micro-angiopathy in the six months prior to study visit\n* Organ failure or other severe diseases limiting life expectancy;\n* Beginning, in the three months before screening visit, of any kind of drug which can modify glycemic levels (beta-blockers, diuretics…), or acute disease (acute infection, urinary tract infection…) in three months before screening visit\n* History of inflammatory/infective/autoimmune chronic disease\n* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, gastric surgery, inflammatory bowel disease;\n* Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at screening that in the judgment of the investigator would preclude safe completion of the study;\n* Uncontrolled or inadequately controlled hypertension at screening (Systolic Blood Pressure (SBP)\\>190 or Diastolic Blood Pressure (DBP) \\>100 mmHg)\n* Ongoing pregnancy or absence of effective contraception in women with childbearing potential\n* Contraindications to the maintenance of the background therapy (Metformin), including -but not limited to- chronic kidney failure or plasma creatinine concentrations \\> 1.5 mg/dL, severe respiratory failure, etc.;\n* Contraindications to the use of a Sulfonylurea;\n* Contraindications to the use of a DPP-IV Inhibitor;\n* Laboratory findings, or other disease conditions, at the screening visit that might interfere with study measurements:\n\n  1. Hemoglobinopathy known to affect HbA1c assays;\n  2. Known chronic liver diseases, including HBV (hepatitis B virus) and HCV (hepatitis C virus) infection;\n  3. Liver makers (aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), Gamma-glutamyltransferase (GGT) , bilirubin) above 2 times the upper normal limit;\n  4. Amylase and/or lipase above 2 times the upper normal limit;\n* Chronic use of systemic and/or inhaled corticosteroids (only topical corticosteroids are allowed);\n* History of low compliance, clinically-relevant psychiatric disorders or any current/ historical finding suggesting the patient as inappropriate to follow the study procedures.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in the Endothelial Progenitor Cell (EPC) Number","description":"The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in HbA1C Compared to Baseline","description":"The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":["hypoglycemia"]}}}